sclcWD9900_S48.txt
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.540
- INTERFERON_GAMMA_RESPONSE+0.490
- FATTY_ACID_METABOLISM+0.360
- IL6_JAK_STAT3_SIGNALING+0.320
- ADIPOGENESIS+0.310
- ANDROGEN_RESPONSE+0.310
- INFLAMMATORY_RESPONSE+0.310
- XENOBIOTIC_METABOLISM+0.270
- ALLOGRAFT_REJECTION+0.260
- CHOLESTEROL_HOMEOSTASIS+0.240
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- UNFOLDED_PROTEIN_RESPONSE-0.120
- DNA_REPAIR-0.040
- HEDGEHOG_SIGNALING-0.040
- APICAL_JUNCTION+0.000
- NOTCH_SIGNALING+0.000
- MYC_TARGETS_V1+0.010
- MYC_TARGETS_V2+0.010
- G2M_CHECKPOINT+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2c10534e-5fb7-49b0-8f57-584cb31f3a08 | — | — | 0.851 |
| 2 | TCGA-E9-A1QZ-01A-21R-A169-07 | — | A | 0.841 |
| 3 | SRR8518426 | — | C | 0.837 |
| 4 | 9afe3e00-86a7-4fdb-a253-0bc8896aafe3 | — | — | 0.834 |
| 5 | BS_KEA474HN | low-grade glioma | — | 0.802 |
| 6 | SRR6013498 | — | cohortA1 | 0.802 |
| 7 | SRR23036886 | — | — | 0.798 |
| 8 | SRR12696766 | — | — | 0.796 |
| 9 | TCGA-75-5126-01A-01R-1755-07 | — | cohortA1 | 0.793 |
| 10 | GSM5359441 | — | — | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.310 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |